Project Grant K99HL175119

Award Date 8/1/24
Completion Date 7/31/26
Dollars Obligated $115K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award of $116,250 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research at The Johns Hopkins University to study the prevalence, risk factors, and progression of calcific aortic valve disease (CAVD) and severe aortic stenosis in persons over 75 years old. The research aims to: 1) identify long-term risk factors for the development of aortic valve calcification, 2) create population percentiles for aortic valve...
This $147,486 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanistic relationship between bicuspid aortic valve (BAV)-induced mechanical stress and the development of premature calcific aortic stenosis. The research project, conducted by the Medical College of Wisconsin, Inc., aims to: 1) Delineate the BAV-specific mechanosensitive signaling pathway between vascular endothelial cells...
This federal Project Grant award under the National Heart Lung and Blood Institute's (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) provides $138,523 to Brigham & Women's Hospital Inc. to systematically compare the mechanisms involved in medial and intimal calcification subtypes, which are distinct drivers of age-related vascular disease and cardiovascular morbidity and mortality. The award, effective from July 2025 through May 2027, will use spatial and extracellular vesicle...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on leveraging deep learning to link normal variation in aortic valve hemodynamics to the pathogenesis of aortic stenosis. The $722,299 award to The Regents of the University of California, San Francisco (UCSF), with a period of performance from August 1, 2025 to July 31, 2030, will enable UCSF to measure aortic valve...
The National Heart Lung and Blood Institute (NHLBI) awarded a $810,650 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The funding will support the development and validation of an artificial intelligence (AI)-enabled algorithm to characterize fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and create an AI-powered risk score to predict...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This $750,345 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The funding supports research to investigate the role of telomerase reverse transcriptase (TERT) in the osteogenic reprogramming of aortic valve interstitial cells, which can lead to calcific aortic valve disease. The project aims to elucidate the epigenetic and transcriptional changes directed by...
This $148,568 federal Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of inflammation and sex-specific differences in the progression of aortic valve stenosis (AVS). The key objectives are to: 1) delineate how secreted factors from valve cells impact macrophage phenotype and vice versa in a sex-dependent manner, and 2) elucidate sex-specific differences in AVS...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $114,938 to Brigham & Women's Hospital Inc. to investigate novel epigenetic mechanisms underlying calcific aortic valve disease (CAVD). The research aims to define the histone code of CAVD, determine downstream translational and post-translational signaling targets, and examine the role of epigenomic modifications on microenvironment signaling mediated by N-linked glycosylation. By mapping the epigenetic regulators and their effects on cellular processes, the project seeks to identify potential pharmacotherapeutic targets to halt CAVD progression. This award, with a project period from August 1, 2024 to July 31, 2026, is part of the hospital's extensive cardiovascular disease research portfolio supported by federal grants.

Generated 7/1/25, 4:38 AM